aTyr Pharma 宣布，公司首席财务官吉尔·布罗德富特（Jill Broadfoot）即将卸任，而布兰登·亚拉斯（Brandon Yaras）将接替其职务，自2026年10月1日起生效。这标志着这家生物制药公司财务领导层迎来新的篇章。布罗德富特在任期间，为公司财务战略与运营稳定做出了重要贡献；如今，她选择功成身退。与此同时，继任者亚拉斯将肩负起引领公司财务规划及资本运作的重任。
aTyr Pharma 宣布，公司首席财务官吉尔·布罗德富特（Jill Broadfoot）即将卸任，而布兰登·亚拉斯（Brandon Yaras）将接替其职务，自2026年10月1日起生效。这标志着这家生物制药公司财务领导层迎来新的篇章。布罗德富特在任期间，为公司财务战略与运营稳定做出了重要贡献；如今，她选择功成身退。与此同时，继任者亚拉斯将肩负起引领公司财务规划及资本运作的重任。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.